AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01566435
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00679302
Drug: Trimethoprim-sulfamethoxazole
RxNorm normalized name: sulfamethoxazole / trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants were randomized to receive placebo or trimethoprim/sulfamethoxazole using a computer randomization program on the initial presentation. The placebo is a Maalox and tonic water combination that resembled the antibiotic in color, texture and taste. The antibiotic dose is a standard trimethoprim/sulfamethoxazole for bacterial infection (10-12mg trimethoprim/kg/day, with a maximum adult dose of 160mg trimethoprim/day, divided into two doses). The concentration of the liquid is 200mg sulfamethoxazole/40mg trimethoprim per 5mL. With a maximum dose of 160mg trimethoprim, this equates to 20mL.
Trial: NCT02876354
Drug: Menaquinone
RxNorm normalized name: Menaquinone
DrugBank: Menaquinone (DB15381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients on hemodialysis will be supplemented by 360 μg /d of menaquinone for 4 weeks. At baseline they will have a lateral abdominal X-Ray and dosage of dp-ucMGP. At the end of the study patients will have a second measurement of dp-ucMGP levels.
Trial: NCT01950507
Drug: Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Entocort EC 3 mg given orally three times daily for at least 14 days
Trial: NCT01950507
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg orally once daily for CrCl greater than or equal to 50 ml/min
Trial: NCT01950507
Drug: Voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in Cohort 1 who are not established on voriconazole will receive a loading dose of 400 mg orally every 12 hours for 2 doses, then 200 mg orally every 12 hours
Trial: NCT01950507
Drug: Micafungin
RxNorm normalized name: Micafungin
DrugBank: Micafungin (DB01141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Micafungin will be dosed as 100 mg as an intravenous infusion once daily at 09:00 for inpatients, and 200 mg to 300 mg as an intravenous infusion administered two to three times weekly for outpatients
Trial: NCT01593215
Drug: Yohimbine
RxNorm normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine capsule
Trial: NCT03440021
Drug: ORM-12741
RxNorm normalized name: ORM-12741
DrugBank: ORM-12741 (DB12057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel selective alpha2c adrenoceptor antagonist
Trial: NCT00881582
Drug: Pegylated interferon alfa-2a plus ribavarin
RxNorm normalized name: Pegylated-interferon alfa 2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-interferon alfa-2a and ribavirin. Pegylated interferon alfa-2a - standard dose; plus ribavirin - standard dose (determined by creatinine clearance); for 24 to 48 weeks (genotypes 1 \& 4: 48 weeks; genotypes 2 \& 3: 24 weeks)
Trial: NCT00646776
Drug: Rifabutin
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule, Oral, 150 mg, once daily, 11 Days
Trial: NCT00646776
Drug: Rifabutin + Atazanavir + Ritonavir
RxNorm normalized name: Rifabutin
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Capsules, Oral, 18 Days~Rifabutin (150 mg, 2x/wk)~Atazanavir (300 mg, once daily)~Ritonavir (100 mg, once daily)
Trial: NCT01566435
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01942135
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib 125 mg/day orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle.
Trial: NCT01942135
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle.
Trial: NCT00126568
Drug: sorafenib tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02319889
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02319889
Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
RxNorm normalized name: Albumin-stabilized nanoparticle (130 nm)
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00615758
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib at the dose of 150 mg orally once a day continually until progression
Trial: NCT02061280
Drug: fluticasone/salmeterol 250/50 Dry Powder Inhaler
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive Advair Diskus 250/50 Dry Powder Inhaler, administered twice daily for 12 weeks after randomization
Trial: NCT02061280
Drug: fluticasone/salmeterol 100/50 Dry Powder Inhaler
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive Advair Diskus 100/50 Dry Powder Inhaler administered twice daily for 12 weeks after randomization
Trial: NCT02061280
Drug: fluticasone 100mcg Dry Powder Inhaler
RxNorm normalized name: fluticasone Dry Powder Inhaler
DrugBank: Fluticasone (DB13867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Flovent Diskus 100mcg Dry Powder Inhaler administered twice daily for 12 weeks after randomization
Trial: NCT01360086
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatine (50mg/m²)
Trial: NCT02772822
Drug: Rituximab plus CHOP
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02757287
Drug: FSH-CTP + DESOGESTREL
RxNorm normalized name: Desogestrel
DrugBank: Desogestrel (DB00304)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormones measured on day of 7th menstrual cycle day , day of pre-ovulatory bolus of GnRH and the day after the bolus ( estradiol, FSH, Progesterone, LH)~- Quality of Life questionnaire the day after the bolus
Trial: NCT00005850
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg/m2 administered by intravenous (IV) over 30 minutes on Day 1 following the gemcitabine infusion. Treatment repeated every 21 days for a total of 6 cycles.
Trial: NCT00072514
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00072514
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00072514
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00005850
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 intravenous (IV) administered by IV over 30 minutes on days 1 and 8. Repeat treatment every 21 days for a total of 6 cycles.
Trial: NCT01408004
Drug: Pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet 800mg qd til progression
Trial: NCT01408004
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tablet 10 mg qd til progression
Trial: NCT01408004
Drug: Pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: tablet 800mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus
Trial: NCT01408004
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tablet 10mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus
Trial: NCT01408004
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus 10mg qd monotherapy until second progression (PD per RECIST 1.1)when first progression after 8 weeks of Pazopanib in alternating regimen
Trial: NCT01408004
Drug: Pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pazopanib 800mg qd monotherapy until second progression (PD per RECIST 1.1) when first progression after 8 weeks of Everolimus in alternating regimen
Trial: NCT01990404
Drug: Premixed 50% nitrous oxide and oxygen
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premixed 50% nitrous oxide and oxygen is a gas in cylinder of 5 litres delivered by a face mask. The gases of the study are contained in anonymous bottles of the same capacity. Bottles will only be differentiated by a letter: A or B.
Trial: NCT01990404
Drug: Medical Air
RxNorm normalized name: Medical air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical air is a gas in cylinder of 5 litres delivered by a face mask. The gases of the study are contained in anonymous bottles of the same capacity. Bottles will only be differentiated by a letter: A or B
Trial: NCT00059332
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Paramedics initiate a loading dose of 4 grams magnesium sulfate IV over 15 minutes, followed after hospital arrival by a maintenance infusion of 16 grams magnesium sulfate IV over 24 hours.
Trial: NCT02642094
Drug: Rapamycin
RxNorm normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Low dose of rapamycin at 2 mg/day for -5-7 days of treatment
Trial: NCT00845988
Drug: aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: dosage form : po recommended dosage : more than 10mg/day duration : 28 weeks
Trial: NCT01196559
Drug: Vinorelbine and Gemcitabine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gmcitabine 1000㎎/㎡ mix in normal saline 100ml iv for 30min andVinorelbine 25㎎/㎡ mix in normal saline 50 ml iv for 5-10min on D1 and 8 every 21 days cycle
Trial: NCT00862563
Drug: Topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses 300 mg topiramate.
Trial: NCT00862563
Drug: Zonisamide
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zonisamide will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses of 2000 400 mg of zonisamide.
Trial: NCT00862563
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses of 2000 mg levetiracetam capsules.
Trial: NCT00862563
Drug: Sugar Pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14.
Trial: NCT01481025
Drug: Cimicifuga Herbarium
RxNorm normalized name: Actaea cimicifuga root extract
DrugBank: Barium sulfate (DB11150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 caps, 80mg/caps, once a day for 1-3 months~1 caps, 80mg/caps, once a day for 3-6 months
Trial: NCT03501069
Drug: TAK-418
RxNorm normalized name: TAK-418 free base
DrugBank: TAK-418 free base (DB16939)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-418 capsules.
Trial: NCT03501069
Drug: TAK-418 Matching Placebo
RxNorm normalized name: TAK-418 free base
DrugBank: TAK-418 free base (DB16939)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-418 matching placebo capsules.
Trial: NCT04233749
Drug: Tranexamic acid tablets
RxNorm normalized name: Tranexamic Acid Tablets
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 325mg of tranexamic acid twice daily for six months
Trial: NCT01751971
Drug: Inspired oxygen (40%)
RxNorm normalized name: oxygen 40 %
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supplemental oxygen at 40% inspired via venturi mask (15 L/min). Equivalent to 5 L/min via nasal cannula.
Trial: NCT01265680
Drug: Erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80.000 UI of Human Recombinant Erythropoietin and intravenous iron at time of arrival at the hospital.
Trial: NCT01307969
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1,8 mL of the local anesthetic formulations were injected at the apex of the maxillary right canine.
Trial: NCT04336098
Drug: SRF617
RxNorm normalized name: Immunoglobulin G4 [229-proline], anti-(human ectonucleoside triphosphate diphosphohydrolase 1) (human monoclonal SRF617 γ4-chain), disulfide with human monoclonal SRF617 κ-chain, dimer
DrugBank: Perenostobart (DB18602)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRF617 prevents CD39 mediated conversion of adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to adenosine monophosphate (AMP) and phosphate, leading to an increase in extracellular ATP and a reduction in adenosine levels within the tumor microenvironment (TME). There is an important role for extracellular ATP and adenosine in cancer maintenance and progression, and maintaining high levels of ATP (and low levels of adenosine) in the TME may have anticancer therapeutic activity.
Trial: NCT04336098
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine as an intravenous (IV) infusion
Trial: NCT04336098
Drug: Albumin-Bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Albumin-bound paclitaxel as an IV infusion
Trial: NCT04336098
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab as an IV infusion .
Trial: NCT02685709
Drug: Octreotide capsules
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00501267
Drug: solabegron and oxybutynin
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02199197
Drug: Radium Ra 223 Dichloride
RxNorm normalized name: Radium Ra 223 dichloride
DrugBank: Radium Ra 223 dichloride (DB08913)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radium Ra 223 Dichloride, 55 kilobecquerel (kBq)/kg body weight, administered as a bolus intravenous (IV) injection (up to 1 minute) on Day 1 of each cycle for 6 cycles.
Trial: NCT04147208
Drug: GLS4
RxNorm normalized name: Galsulfase
DrugBank: Galsulfase (DB01279)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered GLS4 120 mg orally three times daily in fed state
Trial: NCT04147208
Drug: ETV
RxNorm normalized name: Metvixia
DrugBank: Methyl aminolevulinate (DB00992)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally ETV 0.5 mg once daily in fasted state
Trial: NCT02199197
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide 160 mg administered orally once a day (continuously) for 6 cycles.
Trial: NCT02551159
Drug: 5-fluorouracil (5FU)
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy Agent
Trial: NCT02551159
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy agent
Trial: NCT02551159
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy Agent
Trial: NCT02851004
Drug: Napabucasin
RxNorm normalized name: Napabucasin
DrugBank: Napabucasin (DB12155)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 cycle is 21days.~BBI608: Oral administration at a dose of 240mg or 480 mg twice daily (BID), every day.~\[Additional cohort to the Phase II part\] Oral administration at a dose of 240mg mg BID, every day~The therapy will be repeated until meeting the discontinuation criteria.
Trial: NCT02851004
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1 cycle is 21days.~Pembrolizumab: Administration at a dose of 200 mg/body on Day 1 of each cycle~\[Additional cohort to the Phase II part\] Administration at a dose of 200 mg/body on Day 1 of each cycle.~The therapy will be repeated until meeting the discontinuation criteria.
Trial: NCT00262873
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00766480
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00640471
Drug: brivanib alaninate
RxNorm normalized name: Brivanib alaninate
DrugBank: Brivanib alaninate (DB11865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brivanib (BMS-582664) 800 mg po, QD
Trial: NCT00470379
Drug: resiquimod
RxNorm normalized name: Resiquimod
DrugBank: Resiquimod (DB06530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating the dose of resiquimod applied to a fixed area of skin followed by application of topical NY-ESO-1b.
Trial: NCT00653822
Drug: alefacept
RxNorm normalized name: Alefacept
DrugBank: Alefacept (DB00092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IC and SC
Trial: NCT00147199
Drug: Inhaled treprostinil
RxNorm normalized name: treprostinil Inhalation Solution
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Doses are titrated to 9 breaths four times daily. Each breath produces an 18 mcg dose of inhaled treprostinil.
Trial: NCT01105299
Drug: CJ anastrozole 1 mg tablet
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01890421
Drug: Gadobutrol (Gadovist, Gadavist, BAY86-4875)
RxNorm normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
Trial: NCT00207051
Drug: Brivanib + Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets/IV, Oral/IV , Brivanib 800 mg + Erbitux 400 mg/m2 X 1, followed by 250mg/m2, Brivanib QD / Erbitux QW, up to 48 weeks
Trial: NCT00268242
Drug: Gemcitabine Hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg/m2/ min IV for 12 hours
Trial: NCT00268242
Drug: Mitoxantrone Hydrochloride
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 mg/m2/day IV (administer over 30-60 minutes) on Day 1, 2 and 3
Trial: NCT03881995
Drug: Insulin Glargine 100 UNT/ML
RxNorm normalized name: insulin glargine 100 UNT/ML
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose titration will be done based on the subjects fasting blood glucose
Trial: NCT00580606
Drug: Glycerinated peanut allergenic extract
RxNorm normalized name: peanut allergenic extract
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerinated peanut extract delivered sublingually.
Trial: NCT00580606
Drug: Placebo for peanut extract (glycerin)
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (glycerin) delivered sublingually.
Trial: NCT02333123
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each 300mg aspirin capsule will contain over-encapsulated 4 x Aspirin 75mg tablets.
Trial: NCT04621617
Drug: Albumin
RxNorm normalized name: Albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human albumin will be administered by intravenous infusion at a dose of 1.5 gm/kg/week for 2 weeks followed by HA 40 grams every 7days
Trial: NCT04621617
Drug: Midodrine
RxNorm normalized name: Midodrine
DrugBank: Midodrine (DB00211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Midodrine will be given at a dose of 7.5 mg three times in a day
Trial: NCT01252758
Drug: albuterol sufate DPI (TBS-7) dose 1
RxNorm normalized name: albuterol Metered Dose Inhaler
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01252758
Drug: albuterol sufate DPI (TBS-7) dose 2
RxNorm normalized name: albuterol Metered Dose Inhaler
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01252758
Drug: albuterol sufate DPI (TBS-7) dose 3
RxNorm normalized name: albuterol Metered Dose Inhaler
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01252758
Drug: Albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no